Skip to content

Efficacy and Safety Comparison of Three Approaches for Paravertebral Block in the Treatment of Upper Thoracic Herpes Zoster-Associated Neuralgia

Efficacy and Safety Comparison of Three Approaches for Paravertebral Block in the Treatment of Upper Thoracic Herpes Zoster-Associated Neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122311
Enrollment
Unknown
Registered
2026-04-12
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster

Interventions

Intervention Group A (Tilted Approach):Ultrasound-guided paravertebral nerve block (tilted approach), with drug formulation: 10 ml of 0.2% ropivacaine + 0.5 ml of compound betamethasone + 3 mg of aden
Intervention Group B (Inferior Facet - Pleural Midpoint Approach):Ultrasound-guided paravertebral nerve block (inferior facet-pleural midpoint approach), with drug formulation: 10 ml of 0.2% ropivacai
Control Group (IC Approach):Ultrasound-guided paravertebral nerve block (intercostal transverse plane approach, IC approach), with drug formulation: 10 ml of 0.2% ropivacaine + 0.5 ml of compound beta
if IC approach block fails, retreatment using the tilted approach

Sponsors

The First Affiliated Hospital of the Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients clinically diagnosed with acute or subacute herpes zoster neuralgia; 2. Aged >= 18 years; 3. Unilateral involvement, with affected segments ranging from T1 to T4; 4. No prior paravertebral nerve block or other interventional therapy; 5. Agreed to participate in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Thoracic anatomical abnormalities; 2. Patients with mental illness, comprehension disorders, or those unable to clearly express pain scores and cooperate with assessments; 3. Poorly controlled diabetes (e.g., fasting blood glucose >= 10.0 mmol/L); 4. Patients with severe cardiac, cerebral, hepatic, pulmonary, renal or other organ diseases, as well as hematological abnormalities; 5. Local or systemic infection at the puncture site, coagulation dysfunction, or other contraindications to relevant nerve blocks.

Design outcomes

Primary

MeasureTime frame
Pain Visual Analog Scale (VAS) Improvement;

Secondary

MeasureTime frame
Changes in Skin Temperature After Block;Changes in Pinprick Sensation After Block;Needle Insertion Time During Block;Improvement in VAS Score Compared to Baseline;Usage of Analgesic Medications;Evaluation of Sleep Quality Changes;Improvement in Anxiety and Depression;Success Rate of Block;

Countries

China

Contacts

Public ContactGu Nan

The First Affiliated Hospital of the Air Force Military Medical University

gunan@fmmu.edu.cn+86 139 9125 7166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026